03.13.25 -- Distributed Cell Therapy Manufacturing Trade-Offs You Should Know About

Here, we share one of the best ways to ensure sterility in aseptic compounding operations and how 503A and 503B pharmacies can achieve the adaptability they need to scale their operation.

Delve into this exploration of the challenges and opportunities facing CGTs, including manufacturing, supply chain logistics, and the need for greater collaboration among stakeholders.

Genome editing with virus-like particles (VLPs) shows promise for gene therapy. Using electroporation, researchers achieved high VLP yields, and genome editing, advancing therapeutic applications.

Optimizing in vitro transcription (IVT) for mRNA is crucial to improving the stability of these molecules and enabling their large-scale production.

This webinar explores mitigating the risk of product loss, and production delays, as well as the critical role rapid sterility testing plays in ensuring the quality and safety of cell therapy products.

This panel discussion looks ahead at decentralized manufacturing, key regulatory considerations, and the anticipated future where cybersecurity becomes a paramount focus.

Delve into the dynamic transition towards automation in cell and gene therapy manufacturing as well as the challenges it presents to start ups with industry experts in this webinar.

Skillfully crafted cell lines can substantially enhance vector purity and yield. Watch to explore a portfolio of engineered cell lines and their potential to transform the landscape of AAV production.

Diseases that lack a cure, or even treatment, may be addressed with new gene therapeutic classes. This potential has spurred new investments in the drug development and commercialization space.